March 19 (Reuters) - AstraZeneca ( AZN ) said on Tuesday it has agreed to buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc ( FUSN ) for about $2 billion in cash. The drugmaker will pay $21 per Fusion share plus a non-transferable contingent value right of $3 per share. ...

(Reuters) -Australia's Boral on Tuesday recommended investors reject its largest shareholder Seven Group Holdings' A$1.9 billion ($1.25 billion) offer for the company claiming it undervalues the building products group. Seven Group, controlled by billionaire Kerry Stokes and his family, already owns nearly 72% of Boral and had launched a bid last month to acquire full control of Boral. The proposal...

SHANGHAI/BEIJING/HONG KONG (Reuters) - A rare Beijing directive to help Vanke beat a liquidity crisis has left lenders scrabbling for the assets that the state-backed developer has proposed for collateral, as parties pull out all the stops to arrest deterioration in the property sector. China Vanke is gasping for funding after sales in both January and February fell below the...

(Reuters) - The artificial intelligence boom has hit the crypto market with a bang. Coins linked to AI-focused crypto projects have jumped alongside tech stocks like Nvidia, driven by insatiable investor appetite for applications like machine-learning. The rise of many AI crypto tokens has outpaced even that of bitcoin over the past year as the world's biggest cryptocurrency has surged...